Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.7.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Revenues $ 394 $ 948
Operating expenses:    
Research and development (related party of $957 and $1,036), net of grant income of $131 and $65 4,117 3,156
General and administrative (related party of $775 and $565) 10,551 7,685
Total operating expenses 14,668 10,841
Operating loss (14,274) (9,893)
Other income (expense):    
Interest expense (related party of $1,928 and $807) (1,929) (807)
Interest income 39 22
Royalty income 25 21
Total other income (expense) (1,865) (764)
Consolidated net loss (16,139) (10,657)
Net loss attributable to noncontrolling interest 1,607 893
Net loss attributable to iBio, Inc. (14,532) (9,764)
Preferred stock dividends (90) 0
Net loss available to iBio, Inc. (14,622) (9,764)
Comprehensive loss:    
Consolidated net loss (16,139) (10,657)
Other comprehensive loss - foreign currency translation adjustments 0 (4)
Comprehensive loss $ (16,139) $ (10,661)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.16) $ (0.12)
Weighted-average common shares outstanding - basic and diluted 89,112 80,973